본문 바로가기

Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-alpha dependent NF kappa B activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
피인용
Web of Science 14
JCR IF
JCR 2011 3.346
ISSN
0223-5234

저자

  1. 김지혜제1저자부산대학교, 약학대학, 약학부, 제약학전공, KO
  2. 강숙진부산대학교, 약학대학, 약학부, 제약학전공, KO
  3. 홍성채부산대학교, 약학대학, 약학부, 제약학전공, KO
  4. 염수환부산대학교, 약학대학, 약학부, 제약학전공, KO
  5. 김영미부산대학교, 약학대학, 약학부, 제약학전공, KO
  6. 정연진교신저자부산대학교, 약학대학, 약학부, 제약학전공, KO

초록

To develop a more potent NF kappa B inhibitor from salicylic acid which is known to inhibit activity of NF kappa B, a transcription factor regulating genes involved in immunity, inflammation and tumorigenesis, derivatives of salicylic acid (SA) where the 5 position, carboxyl or hydroxyl group was modified were treated in HCT116 cells transfected with an NF kappa B dependent luciferase gene and LPS-stimulated RAW264.7 cells. Amidation of the carboxylic group or substitution of chlorine at the 5 position increased the ability of SA to suppress the expression of NF kappa B dependent luciferase and inducible nitric oxide synthase, a product of an NF kappa B target gene. Moreover, simultaneous amidation and chlorination of SA (5-chlorosalicylamide; 5-CSAM) conferred an additive NF kappa B inhibitory activity on SA. To further enhance the inhibitory activity. N-modification was imposed on 5-CSAM. N-(5-chlorosalicyloyl)phenethylamine (5-CSPA), N-(5-chlorosalicyloyl)3-phenylpropylamine (5-CSPPA) and N-(5-chlorosalicyloyl)4-hydroxyphenylethylamine (5-CSHPA) showed greater potencies for inhibiting NF kappa B activity than other derivatives. Their IC(50)s' in the luciferase assay measured 15 mu M (5-CSPA), 17 mu M (5-CSPPA) and 91 mu M (5-CSHPA). Rectal administration of 5-CSPA ameliorated TNBS-induced rat colitis, which was more effective than a conventional drug, 5-aminosalicylic acid. These data may provide useful information for development of a therapeutic agent for treatment of diseases where NF kappa B plays a critical role in the pathogenic progresses. (C) 2011 Elsevier Masson SAS. All rights reserved.

키워드

Salicylic acid derivativesStructure-activity relationshipInflammatory bowel diseaseNF kappa BINFLAMMATORY BOWEL DISEASESCOLON-SPECIFIC PRODRUG5-AMINOSALICYLIC ACIDSULFASALAZINEACTIVATIONPATHWAYIMMUNECELLSGAMMABETA

식별자

WoS UID
000300484900004